Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi XDC CaymanSTU:L74 -5.06%50 EBITDA Margin % is 27.09% as of Dec. 2025, which is 9% below its 10-year median of 29.87. GuruFocus rates STU:L74 with a GF Score™ of 50/100. The stock has 3 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, WuXi XDC Cayman ranks better than 84.8% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. WuXi XDC Cayman's EBITDA for the
six
months ended in Dec. 2025 was €106.6 Mil. WuXi XDC Cayman's Revenue for the
six
months ended in Dec. 2025 was €393.3 Mil. Therefore, WuXi XDC Cayman's EBITDA margin for the quarter that ended in Dec. 2025 was 27.09%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
WuXi XDC Cayman EBITDA Margin % Related Terms
WuXi XDC Cayman EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for WuXi XDC Cayman's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:L74 vs TMO, DHR, NTRA: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, WuXi XDC Cayman's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi XDC Cayman EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, WuXi XDC Cayman's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where WuXi XDC Cayman's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi XDC Cayman (STU:L74) has a EBITDA Margin % of 27.09% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on WuXi XDC Cayman and its competitors. This is near median its historical median of 29.87. Over the past decade, WuXi XDC Cayman's EBITDA Margin % has ranged from 19.77 to 47.57. According to the industry distribution chart, WuXi XDC Cayman ranks #31 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 15.2%.
Is WuXi XDC Cayman's EBITDA Margin % too high?
WuXi XDC Cayman's current EBITDA Margin % of 27.09% is near median its 10-year median of 29.87. Over the past 10 years, this metric has ranged from a low of 19.77 to a high of 47.57. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.69. WuXi XDC Cayman's value of 27.09% is 376.5% above this industry median. Based on the distribution chart, WuXi XDC Cayman ranks #31 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, WuXi XDC Cayman has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does WuXi XDC Cayman's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, WuXi XDC Cayman ranks #31 out of 204 companies for EBITDA Margin %. This places WuXi XDC Cayman in the top 15% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.69. WuXi XDC Cayman's value of 27.09% is 376.5% above this benchmark. Historically, WuXi XDC Cayman's own EBITDA Margin % has ranged from 19.77 to 47.57 over the past decade. While the company's 10-year median is 29.87 vs. the industry median of 5.69, WuXi XDC Cayman has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.69, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi XDC Cayman's current EBITDA Margin % of 27.09% is 376.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on WuXi XDC Cayman and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi XDC Cayman's current EBITDA Margin % is 27.09%, which is near median its own 10-year median of 29.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi XDC Cayman stock overvalued right now?
WuXi XDC Cayman (STU:L74) has a current EBITDA Margin % of 27.09%. The current EBITDA Margin % is 27.09%, which is near median its 10-year median of 29.87 and 376.5% above the Medical Diagnostics & Research industry median of 5.69. WuXi XDC Cayman's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For WuXi XDC Cayman (STU:L74), the current EBITDA Margin % is 27.09% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.
50GF Score
Get the complete analysis for STU:L74
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:L74 has been successfully added to your 
